2025 will mark a decade since Regeneron formed a discovery, development, and commercialization cancer alliance with Sanofi for immuno-oncology antibody treatments. With the partnership now in the rear view mirror, the company is focused on differentiating its foundational anti-PD-1 product in international markets, as well as finding efficacious combinations in the crowded oncology market.
Key Takeaways
· Regeneron remains committed to its oncology strategy of using combination therapies to engage the immune system in fighting cancer. Its foundational PD-1 inhibitor, Libtayo, is central to this approach.
· With the end of its partnership with Sanofi, Regeneron is focusing on differentiating Libtayo in international markets, leveraging its strong clinical data and expanding its commercial team to establish a global footprint
Israel Lowy, senior vice president of translational and clinical sciences in Regeneron’s oncology division, emphasizes to In Vivo that the company has “remained true” to its almost-10-year-old oncology strategy, the core belief being that effectively engaging the immune
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
